FDA Approves Bayer's Macrocyclic GBCA Gadoquatrane (AMBELVIST)

FDA approved Bayer's macrocyclic gadolinium-based contrast agent AMBELVIST (gadoquatrane), offering a new option for contrast-enhanced MRI across clinical settings.

• Gadoquatrane is a high-relaxivity macrocyclic GBCA designed for improved stability.
• Bayer positions the approval as strengthening its connected MR portfolio to support imaging programs.
• No specific diagnostic performance or safety statistics were provided in the trade press announcement.

RadPigeon summaries are original and for information only. They are not clinical advice.